Subsequent Events (Details) - USD ($) |
1 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Jul. 28, 2022 |
Jul. 17, 2022 |
Jul. 01, 2022 |
Jul. 31, 2022 |
Jul. 31, 2022 |
Jun. 30, 2022 |
Dec. 31, 2021 |
|
Subsequent Events (Details) [Line Items] | |||||||
Term agreement, description | The term of the agreement is for three years; upon signing the agreement, a payment of £142,500 ($173,077) is due, with the same amount due at 6 months and one year after the signing of the agreement. A final payment in the same amount will be due upon submission of a final written report to Cannbiorex | ||||||
Reimbursement claim | $ 55,112 | ||||||
Common stock par value | $ 0.0001 | $ 0.0001 | |||||
Subsequent Event [Member] | |||||||
Subsequent Events (Details) [Line Items] | |||||||
Sale of common stock | 3,500,000 | ||||||
Purchase of common stock shares | 2,632,076 | ||||||
Purchase of warrants | 6,132,076 | ||||||
Warrants price per share | $ 1.06 | ||||||
Gross proceeds | $ 6,500,000 | ||||||
Excess of ownership, percentage | 4.99% | ||||||
Warrants exercisable, term | 5 years | 5 years | |||||
Subsequent Event [Member] | Pre-Funded Warrants [Member] | |||||||
Subsequent Events (Details) [Line Items] | |||||||
Warrant exercise price | $ 0.0001 | ||||||
Excess of ownership, percentage | 9.99% | ||||||
Director [Member] | |||||||
Subsequent Events (Details) [Line Items] | |||||||
Common stock par value | $ 0.0001 |
X | ||||||||||
- Definition Excess of ownership percentage. No definition available.
|
X | ||||||||||
- Definition Amount of gross proceeds. No definition available.
|
X | ||||||||||
- Definition The amount of reimbursement claim. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Number of warrants to purchase shares of common stock. No definition available.
|
X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
X | ||||||||||
- Definition Information about borrowings which initially required repayment in less than twelve months (or normal operating cycle, if longer) after its issuance and that does not otherwise qualify as long-term debt. It typically is comprised of borrowings under letters of credit, lines of credit, commercial paper, and notes payable of short duration. Disclosures include amounts of borrowings under each arrangement, description of underlying arrangements, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements such as the effects of refinancings and noncompliance with debt covenants. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|